Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [ChIPseq DC]

ABSTRACT: Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [ChIPseq DC]

PROVIDER: PRJNA813678 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18268564.fastq.gz	Fastqsanger.gz
	SRR18268566.fastq.gz	Fastqsanger.gz
	SRR18268567.fastq.gz	Fastqsanger.gz

Items per page:

1 - 3 of 3

Similar Datasets

Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [scRNAseq DC]

Project description:Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [scRNAseq DC]

| PRJNA813683 | ENA

Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [ATACseq DC]

Project description:Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [ATACseq DC]

| PRJNA813684 | ENA

Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [RNAseq DC]

Project description:Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [RNAseq DC]

| PRJNA813679 | ENA

Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML

Project description:Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML

| PRJNA813640 | ENA

Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [RNAseq IFNAR KO tumor cells]

Project description:Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [RNAseq IFNAR KO tumor cells]

| PRJNA813680 | ENA

Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [ChIPseq DC]

Project description:Pharmacological inhibition of epigenetic enzymes can have therapeutic benefit against hematological malignancies. Apart from affecting tumor cell growth and proliferation, these epigenetic agents may mediate anti-tumor immunity. Here we discovered a novel immuno-regulatory mechanism through inhibition of histone deacetylases (HDACs). In models of AML, leukemia cell differentiation and therapeutic benefit mediated by the HDAC inhibitor panobinostat required activation of the type I interferon (IFN) pathway. Plasmacytoid dendritic cells (pDCs) produced type I IFN after panobinostat treatment, through transcriptional activation of IFN genes concomitant with increased H3K27 acetylation at these loci. Depletion of pDCs abrogated panobinostat-mediated activation of type I IFN signaling in leukemia cells and impaired therapeutic efficacy, while combined treatment of panobinostat and IFN improved outcomes in mouse and human models. These discoveries offer a new therapeutic approach for AML and demonstrate that epigenetic rewiring of pDCs enhances anti-tumor immunity, opening the possibility of exploiting this population for immunotherapies. profiling by high throughput sequencing.

2022-03-10 | GSE198116 | GEO

Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [RNAseq WT tumor cells]

Project description:Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML [RNAseq WT tumor cells]

| PRJNA813681 | ENA